Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
17.87
-0.38 (-2.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
858,254
Open
18.19
Bid (Size)
16.50 (1)
Ask (Size)
17.87 (1)
Prev. Close
18.25
Today's Range
17.55 - 18.34
52wk Range
5.120 - 18.82
Shares Outstanding
60,717,176
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Thursday's After-Market Session
October 17, 2024
Via
Benzinga
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+86.92%
+86.92%
1 Month
+24.10%
+24.10%
3 Month
+82.16%
+82.16%
6 Month
+208.10%
+208.10%
1 Year
+162.41%
+162.41%
More News
Read More
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
October 16, 2024
Via
Benzinga
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
October 10, 2024
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
September 27, 2024
Via
Benzinga
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
October 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
October 09, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
September 27, 2024
Via
Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
September 27, 2024
Via
Benzinga
Analyst Ratings For Travere Therapeutics
September 06, 2024
Via
Benzinga
Expert Ratings For Travere Therapeutics
August 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 26, 2024
Via
Benzinga
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
September 09, 2024
Via
Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
September 06, 2024
Via
Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
September 06, 2024
Via
Investor's Business Daily
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
September 06, 2024
Via
Benzinga
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 22, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Travere Therapeutics Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.